Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Cutera's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CUTR's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CUTR underperformed the US Medical Equipment industry which returned -8% over the past year.
Return vs Market: CUTR underperformed the US Market which returned -12.7% over the past year.
Price Volatility Vs. Market
How volatile is Cutera's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StDavid Mowry Is The CEO & Director of Cutera, Inc. (NASDAQ:CUTR) And They Just Spent US$100k On Shares
1 month ago | Simply Wall StCutera, Inc. Just Reported, And Analysts Assigned A US$29.50 Price Target
1 month ago | Simply Wall StShould You Be Concerned About Cutera, Inc.'s (NASDAQ:CUTR) Historical Volatility?
Is Cutera undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CUTR ($12.62) is trading above our estimate of fair value ($5)
Significantly Below Fair Value: CUTR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CUTR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: CUTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CUTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CUTR is overvalued based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (2.9x).
How is Cutera forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CUTR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: CUTR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CUTR's is expected to become profitable in the next 3 years.
Revenue vs Market: CUTR's revenue (6.7% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: CUTR's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CUTR's Return on Equity is forecast to be low in 3 years time (13.5%).
How has Cutera performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CUTR is currently unprofitable.
Growing Profit Margin: CUTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CUTR is unprofitable, and losses have increased over the past 5 years at a rate of -14.8% per year.
Accelerating Growth: Unable to compare CUTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CUTR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: CUTR has a negative Return on Equity (-26.88%), as it is currently unprofitable.
How is Cutera's financial position?
Financial Position Analysis
Short Term Liabilities: CUTR's short term assets ($95.0M) exceed its short term liabilities ($58.6M).
Long Term Liabilities: CUTR's short term assets ($95.0M) exceed its long term liabilities ($9.2M).
Debt to Equity History and Analysis
Debt Level: CUTR is debt free.
Reducing Debt: CUTR has not had any debt for past 5 years.
Inventory Level: CUTR has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CUTR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CUTR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CUTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cutera's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CUTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CUTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CUTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CUTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CUTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Mowry (57yo)
Mr. David H. Mowry, also known as Dave, is the Chief Executive Officer and Director at Cutera, Inc. since July 9, 2019. Mr. Mowry served as the Director, President and Chief Executive Officer of Vyaire Med ...
|CEO & Director||0.67yr||no data||0.64% $1.1m|
|Interim Chief Financial Officer||0.25yr||no data||no data|
|Executive VP & Chief Technology Officer||2.58yrs||no data||no data|
|Vice President of Investor Relations & Corporate Development||no data||no data||no data|
|VP, General Counsel & Secretary||no data||no data||no data|
|Director of Corporate Communications||no data||no data||no data|
|Senior VP of Global Marketing & Clinical Development||2yrs||no data||no data|
|Head of Human Officer||2yrs||no data||no data|
|Vice President of Finance||no data||no data||no data|
Experienced Management: CUTR's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|CEO & Director||0.67yr||no data||0.64% $1.1m|
|Independent Director||1yr||no data||0.61% $1.1m|
|Independent Director||21.25yrs||US$150.99k||0.036% $63.4k|
|Independent Director||1yr||no data||0.069% $121.2k|
|Non-Executive Director||8.42yrs||US$173.74k||0.29% $511.9k|
|Independent Director||15.83yrs||US$161.49k||0.27% $471.7k|
|Independent Chairman||3.42yrs||US$200.99k||0.071% $125.4k|
Experienced Board: CUTR's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CUTR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Cutera, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cutera, Inc.
- Ticker: CUTR
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$175.737m
- Shares outstanding: 14.42m
- Website: https://www.cutera.com
Number of Employees
- Cutera, Inc.
- 3240 Bayshore Boulevard
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CUTR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2004|
|TJ9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 2004|
Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin revitalization. In addition, the company offers GenesisPlus, CoolGlide, myQ, enlighten SR, and truSculpt iD products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 02:37|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.